Browse by Medical Category
The Vasculitis and Glomerulonephritis Center at Massachusetts General Hospital combines the expertise of specialists from the Divisions of Rheumatology and Nephrology to provide individualized, high-quality care to patients with vasculitis, glomerulonephritis and more than 30 related conditions. Our team of experts is dedicated to excellence in patient care through early diagnosis, personalized treatment and leading-edge research in vasculitis, glomerulonephritis and related conditions.
An individual's diagnosis—in particular, the severity of the disease and the extent that organs are affected—will determine the prognosis and treatment plan. With early diagnosis and expert management, many patients can expect to maintain long-term remission of vasculitis and glomerulonephritis. In order to maximize the effectiveness of treatment and to minimize medication side effects, our approach relies on developing a personalized treatment plan for each patient.
Our center provides patients with one access point to a core group of specialists who have extensive experience in treating patients with vasculitis and glomerulonephritis. As necessary, we will coordinate care with our team of subspecialty experts, including:
The diagnosis and treatment of vasculitis and glomerulonephritis requires a careful review of a patient’s symptoms and previous testing. During a patient’s first appointment at the Mass General Vasculitis and Glomerulonephritis Center, we will review his/her medical history, perform a physical examination and decide what additional tests are necessary to make an accurate diagnosis. We will also conduct a careful review of the patient’s medical records, therefore we ask all patients to bring their medical notes, as well as related test results and biopsy samples.
An important component to leading-edge patient care is the development of new diagnostic tools and effective treatment strategies. Our physicians have led a number of studies that have helped establish the current standard of treatment in the diagnosis and treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Our patients have access to ongoing clinical trials in treatment for several types of vasculitis and glomerulonephritis.
Accepting New Patients
Accepting New Patients - Call for Availability
The Vasculitis and Glomerulonephritis Center cares for more than 30 conditions related to vasculitis and glomerulonephritis.
Glomerulonephritis is a type of glomerular kidney disease in which the kidneys' filters become inflamed and scarred, and slowly lose their ability to remove wastes and excess fluid from the blood to make urine.
Vasculitis refers to a group of diseases that result in inflammation, or swelling, of blood vessels. The inflammation damages the vessels, thus affecting the organs supplied by these blood vessels.
For more information on enrolling in a clinical trial, please speak to a member of your Mass General care team or contact us at 617-726-0738.
The Vasculitis and Glomerulonephritis Center at Massachusetts General Hospital is dedicated to improving the treatment of vasculitis and glomerulonephritis through leading-edge research. Our physicians are engaged in research studies ranging from understanding the biology of vasculitis through laboratory-based research to testing new treatments in clinical trials.
We are actively enrolling patients in the following research studies:
This trial examines whether a two-month course of prednisone, in combination with rituximab. is as effective in treating anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis as the currently used 6 to 24 month prednisone treatment courses. Because prednisone (a corticosteroid) causes significant side effects when used over a long period of time, a shorter duration of prednisone therapy, if effective, may considerably reduce steroid side effects.
A great unmet need currently exists in giant cell arteritis for glucocorticoid-sparing medications. This study is a phase III, multicenter, randomized, double-blind placebo-controlled trial to assess the efficacy and safety of tociiizumab in patients with giant cell arteritis (also known as temporal arteritis). Two hundred and fifty patients are being enrolled at several centers in the United States and Europe. GiACTA will determine whether tociiizumab is a corticosteroid-sparing alternative for patients with giant cell arteritis.
The exact role of vascular imaging with respect to monitoring of disease activity and prediction of disease relapse has not clearly been defined in giant cell arteritis. For this reason, patients with giant cell arteritis who are enrolled in the GiACTA trial can participate in a positron emission tomography-computed tomography (PET/CT) substudy. Selected patients will undergo a PET/CT of the neck, chest, abdomen and pelvis after one year of treatment to scan the large arteries for radiographic evidence of vascular inflammation. The goal of this substudy is to determine the proportion of patients with radiographic activity and the correlation of radiographic findings with the risk of subsequent disease relapse.
Recent studies have demonstrated that rituximab therapy may be effective in some patients with ANCA-associated vasculitis, however the optimal duration of treatment remains unknown. This study will enroll patients who have received rituximab for 18 months or longer to determine the most effective strategy for reducing the rituximab dose while keeping vasculitis under good control.
We have two locations at Massachusetts General Hospital. If you are scheduling an appointment, our staff will confirm at which location your appointment will be held.
Suite 4FBoston, MA 02144 See Maps & Directions
Boston, MA 02114 See Maps & Directions
Back to Top